1150586-64-3
Chemical Structure
CB86
- CAS No.: 1150586-64-3
- Formula:C26H43NO3
- Molecular Weight:417.63
IUPAC Name: N-cyclopropyl-8-(3-hydroxy-5-(2-methyloctan-2-yl)phenoxy)octanamide
InChIKey: PVAOGZXUOOHSMN-UHFFFAOYSA-N
SMILES: O=C(NC1CC1)CCCCCCCOC2=CC(O)=CC(=C2)C(C)(C)CCCCCC
Biological Activity: CB86 is a small-molecule ligand of the translocator protein TSPO, binding to 18-kDa TSPO with high affinity (IC50 1.6 nM). CB86 competitively binds the TSPO protein on the mitochondrial outer membrane, inhibits LPS-induced M1 pro-inflammatory activation of BV‑2 microglia, and simultaneously inhibits 6‑OHDA-induced ROS generation, apoptosis, and necrosis in PC12 cells, exerting anti-inflammatory and neuroprotective effects. CB86 can be used in research related to Parkinson's disease and rheumatoid arthritis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CB86 | CB86 is a small-molecule ligand of the translocator protein TSPO, binding to 18-kDa TSPO with high affinity (IC50 1.6 nM). CB86 competitively binds the TSPO protein on the mitochondrial outer membrane, inhibits LPS-induced M1 pro-inflammatory activation of BV‑2 microglia, and simultaneously inhibits 6‑OHDA-induced ROS generation, apoptosis, and necrosis in PC12 cells, exerting anti-inflammatory and neuroprotective effects. CB86 can be used in research related to Parkinson's disease and rheumatoid arthritis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Monga S, et al. The Neuro-Protective Effects of the TSPO Ligands CB86 and CB204 on 6-OHDA-Induced PC12 Cell Death as an In Vitro Model for Parkinson's Disease. Biology. 2021 Nov 15;10(11):1183.
- [2]. Monga S, et al. The protective effect of the TSPO ligands 2,4-Di-Cl-MGV-1, CB86, and CB204 against LPS-induced M1 pro-inflammatory activation of microglia. Brain Behav Immun Health. 2020 May 21;5:100083.
- [3]. Hou Z, et al. Gadolinium-conjugated CB86: a novel TSPO-targeting MRI contrast agent for imaging of rheumatoid arthritis. Journal of drug targeting. 2020 Apr;28(4):398-407.
